Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Change in FEV1 (in liters) from baseline
研究概览
简要总结
The objective of this trial is to determine the safety and effect on pulmonary function of 14 days of inhaled L-arginine versus placebo administered over a period of 14 days in a cohort of CF patients.
详细描述
Despite the inflammatory nature of lung disease in CF, nitric oxide (NO) formation as well as the expression of NOS2 has been found to be decreased in CF airways. While the reasons for impaired airway NO formation remain incompletely understood, there is evidence that low NO formation contributes to lung pathophysiology in CF. Constitutive endogenous formation of Nitric oxide (NO) in airways is thought to play a role in neurotransmission, smooth muscle relaxation and bronchodilation. Previous animal experiments have shown that the addition of L-arginine, the precursor of enzymatic NO formation, resulted in a significantly greater relaxation of tracheas. There is also evidence that a single dose of inhaled L-arginine improves pulmonary function in CF. In this study we will assess the effect of L-arginine inhalation on lung function, nitric oxide formation, airway inflammation and bacterial infection in CF patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of CF as defined by two or more clinical features of CF and a documented sweat chloride concentration > 60 mEq/L and/or two well characterized disease causing CFTR gene mutations
- •14 years of age and older at enrollment
- •Clinically stable at enrollment
- •Ability to comply with medication use, study visits and study procedures
- •FEV1 % predicted > 40% < 80 % as calculated by reference equations
排除标准
- •Respiratory culture positive for: B. cepacia complex within past year or at screening
- •Use of systemic corticosteroids within 30 days of screening
- •Use of intravenous antibiotics or oral quinolones within 14 days of screening
- •History of biliary cirrhosis, portal hypertension, or splenomegaly
- •Other major organ dysfunction
- •History of lung transplantation or currently on lung transplant list
- •Supplemental oxygen therapy
- •Oxygen saturation < 95 % on room air
- •Positive pregnancy test at screening
- •Investigational drug use within 30 days of screening
- •History of alcohol, illicit drug or medication abuse within 1 year of screening
- •Acute respiratory symptoms
- •Inability to take any form of bronchodilator
- •Wheezing at the time of study
研究组 & 干预措施
1
干预措施: L-arginine (Drug)
2
干预措施: L-arginine (Drug)
结局指标
主要结局
Change in FEV1 (in liters) from baseline
时间窗: At the end of the 14 day treatment period
Adverse events such as gastrointestinal complaints, wheezing, hepatitis or shortness of breath
时间窗: 70 weeks
次要结局
- Change in FVC and change in FEV25-75 from baseline to completion of the 2 week treatment period.(Will be measured at the end of the 14 day treatment period)
- Change in exhaled nitric oxide (FeNO)(70 days)
- Changes in inflammatory markers in sputum from baseline including neutrophils (sputum), neutrophil elastase (sputum) and interleukin (IL)-8 concentrations (sputum).(Will me measured at the end of the 14 day treatment period)
- Changes in sputum concentrations of L-arginine metabolites(70 days)
研究者
Felix Ratjen
Division Head, Respiratory Medicine
The Hospital for Sick Children